Growing evidence showed that EZH2 is upregulated in a wide spectrum of solid tumors including non-small cell lung cancer[9], prostate cancer [10], head and neck squamous cell carcinoma [11], breast cancer [12], liver cancer [13], and gastric cancer [14]. This evidence concerns the gene EZH2 and breast cancer.